Anbio Biotechnology (NNNN)
| Market Cap | 1.62B |
| Revenue (ttm) | 8.19M |
| Net Income (ttm) | 2.37M |
| Shares Out | 43.89M |
| EPS (ttm) | 0.06 |
| PE Ratio | 684.22 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 104,801 |
| Open | 34.96 |
| Previous Close | 36.20 |
| Day's Range | 34.96 - 38.50 |
| 52-Week Range | 5.18 - 38.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NNNN
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021... [Read more]
Financial Performance
In 2024, Anbio Biotechnology's revenue was $8.19 million, an increase of 21.95% compared to the previous year's $6.71 million. Earnings were $2.37 million, an increase of 5.29%.
Financial numbers in USD Financial StatementsNews
Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions
Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Coll...
U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings
The calendar slowed down this past week, with only small listings in the US. There was one sizable filing this past week - AIRO Group Holdings. No IPOs are currently scheduled to list in the week ahea...
Anbio Biotechnology Announces Closing of Initial Public Offering
Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the pro...
Anbio Biotechnology Announces Pricing of Initial Public Offering
Frankfurt am Main, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the pro...
U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings
Two small IPOs listed this week - INLIF and OneConstruction Group. Five issuers and two SPACs submitted initial filings this week. The 2025 IPO market is here, and while there are a few small deals on...
Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch
Anbio Biotechnology plans to raise $8.8 million in an IPO to commercialize its in vitro diagnostics products amid market risks. The company has experienced fluctuating revenue and profitability, with ...
Anbio Biotechnology IPO Registration Document (F-1)
Anbio Biotechnology has filed to go public with an IPO on the NASDAQ.